Myeloid neoplasia in children treated for solid tumours

C. H. Pui, E. Thompson, J. Wilimas, L. C. Bowman, W. M. Crist, C. B. Pratt, C. H. Pui, S. C. Raimondi, D. R. Head, L. E. Kun, M. L. Hancock, C. H. Pui, E. Thompson, J. Wilimas, L. C. Bowman, W. M. Crist, C. B. Pratt

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Therapy-related myeloid neoplasia developed 14 to 189 months after diagnosis of the primary malignancy in 12 out of 3365 children treated for malignant solid tumours; 6 of the 12 were in their first complete remission. The 10-year cumulative incidence of myeloid neoplasia was 1·3% (95% Cl 0·5-3·6) for the 447 patients with Hodgkin's disease, 1·3% (0·4-4·3) for the 420 with non-Hodgkin lymphoma, and 1·2% (0·3-5·2) for the 440 with neuroblastoma. This complication appeared in 1 of 180 children with brain tumours and in none of the 1878 with other malignancies. Risk of therapy-related myeloid neoplasia in patients with Hodgkin's disease was associated with recurrence of the primary malignancy, a combination of radiotherapy and chemotherapy with alkylating agents, and age ≥12 years at diagnosis of Hodgkin's disease. Of the 8 patients who underwent chromosomal analysis of neoplastic myeloid cells, 2 showed complete loss of chromosome 7 and 4 showed t(9;11) or t(8;21) with or without del(16)(q22). The 2 patients who had received an epipodophyllotoxin had an 11q23 abnormality. The risk of therapy-related myeloid neoplasia is low in children with malignant solid tumours.

Original languageEnglish (US)
Pages (from-to)417-421
Number of pages5
JournalThe Lancet
Volume336
Issue number8712
DOIs
StatePublished - Aug 18 1990

Fingerprint

Neoplasms
Hodgkin Disease
Podophyllotoxin
Chromosomes, Human, Pair 4
Chromosomes, Human, Pair 7
Alkylating Agents
Myeloid Cells
Combination Drug Therapy
Neuroblastoma
Brain Neoplasms
Non-Hodgkin's Lymphoma
Radiotherapy
Therapeutics
Recurrence
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pui, C. H., Thompson, E., Wilimas, J., Bowman, L. C., Crist, W. M., Pratt, C. B., ... Pratt, C. B. (1990). Myeloid neoplasia in children treated for solid tumours. The Lancet, 336(8712), 417-421. https://doi.org/10.1016/0140-6736(90)91956-B

Myeloid neoplasia in children treated for solid tumours. / Pui, C. H.; Thompson, E.; Wilimas, J.; Bowman, L. C.; Crist, W. M.; Pratt, C. B.; Pui, C. H.; Raimondi, S. C.; Head, D. R.; Kun, L. E.; Hancock, M. L.; Pui, C. H.; Thompson, E.; Wilimas, J.; Bowman, L. C.; Crist, W. M.; Pratt, C. B.

In: The Lancet, Vol. 336, No. 8712, 18.08.1990, p. 417-421.

Research output: Contribution to journalArticle

Pui, CH, Thompson, E, Wilimas, J, Bowman, LC, Crist, WM, Pratt, CB, Pui, CH, Raimondi, SC, Head, DR, Kun, LE, Hancock, ML, Pui, CH, Thompson, E, Wilimas, J, Bowman, LC, Crist, WM & Pratt, CB 1990, 'Myeloid neoplasia in children treated for solid tumours', The Lancet, vol. 336, no. 8712, pp. 417-421. https://doi.org/10.1016/0140-6736(90)91956-B
Pui CH, Thompson E, Wilimas J, Bowman LC, Crist WM, Pratt CB et al. Myeloid neoplasia in children treated for solid tumours. The Lancet. 1990 Aug 18;336(8712):417-421. https://doi.org/10.1016/0140-6736(90)91956-B
Pui, C. H. ; Thompson, E. ; Wilimas, J. ; Bowman, L. C. ; Crist, W. M. ; Pratt, C. B. ; Pui, C. H. ; Raimondi, S. C. ; Head, D. R. ; Kun, L. E. ; Hancock, M. L. ; Pui, C. H. ; Thompson, E. ; Wilimas, J. ; Bowman, L. C. ; Crist, W. M. ; Pratt, C. B. / Myeloid neoplasia in children treated for solid tumours. In: The Lancet. 1990 ; Vol. 336, No. 8712. pp. 417-421.
@article{29d5a79e6afd43c0b00a946ac6389992,
title = "Myeloid neoplasia in children treated for solid tumours",
abstract = "Therapy-related myeloid neoplasia developed 14 to 189 months after diagnosis of the primary malignancy in 12 out of 3365 children treated for malignant solid tumours; 6 of the 12 were in their first complete remission. The 10-year cumulative incidence of myeloid neoplasia was 1·3{\%} (95{\%} Cl 0·5-3·6) for the 447 patients with Hodgkin's disease, 1·3{\%} (0·4-4·3) for the 420 with non-Hodgkin lymphoma, and 1·2{\%} (0·3-5·2) for the 440 with neuroblastoma. This complication appeared in 1 of 180 children with brain tumours and in none of the 1878 with other malignancies. Risk of therapy-related myeloid neoplasia in patients with Hodgkin's disease was associated with recurrence of the primary malignancy, a combination of radiotherapy and chemotherapy with alkylating agents, and age ≥12 years at diagnosis of Hodgkin's disease. Of the 8 patients who underwent chromosomal analysis of neoplastic myeloid cells, 2 showed complete loss of chromosome 7 and 4 showed t(9;11) or t(8;21) with or without del(16)(q22). The 2 patients who had received an epipodophyllotoxin had an 11q23 abnormality. The risk of therapy-related myeloid neoplasia is low in children with malignant solid tumours.",
author = "Pui, {C. H.} and E. Thompson and J. Wilimas and Bowman, {L. C.} and Crist, {W. M.} and Pratt, {C. B.} and Pui, {C. H.} and Raimondi, {S. C.} and Head, {D. R.} and Kun, {L. E.} and Hancock, {M. L.} and Pui, {C. H.} and E. Thompson and J. Wilimas and Bowman, {L. C.} and Crist, {W. M.} and Pratt, {C. B.}",
year = "1990",
month = "8",
day = "18",
doi = "10.1016/0140-6736(90)91956-B",
language = "English (US)",
volume = "336",
pages = "417--421",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8712",

}

TY - JOUR

T1 - Myeloid neoplasia in children treated for solid tumours

AU - Pui, C. H.

AU - Thompson, E.

AU - Wilimas, J.

AU - Bowman, L. C.

AU - Crist, W. M.

AU - Pratt, C. B.

AU - Pui, C. H.

AU - Raimondi, S. C.

AU - Head, D. R.

AU - Kun, L. E.

AU - Hancock, M. L.

AU - Pui, C. H.

AU - Thompson, E.

AU - Wilimas, J.

AU - Bowman, L. C.

AU - Crist, W. M.

AU - Pratt, C. B.

PY - 1990/8/18

Y1 - 1990/8/18

N2 - Therapy-related myeloid neoplasia developed 14 to 189 months after diagnosis of the primary malignancy in 12 out of 3365 children treated for malignant solid tumours; 6 of the 12 were in their first complete remission. The 10-year cumulative incidence of myeloid neoplasia was 1·3% (95% Cl 0·5-3·6) for the 447 patients with Hodgkin's disease, 1·3% (0·4-4·3) for the 420 with non-Hodgkin lymphoma, and 1·2% (0·3-5·2) for the 440 with neuroblastoma. This complication appeared in 1 of 180 children with brain tumours and in none of the 1878 with other malignancies. Risk of therapy-related myeloid neoplasia in patients with Hodgkin's disease was associated with recurrence of the primary malignancy, a combination of radiotherapy and chemotherapy with alkylating agents, and age ≥12 years at diagnosis of Hodgkin's disease. Of the 8 patients who underwent chromosomal analysis of neoplastic myeloid cells, 2 showed complete loss of chromosome 7 and 4 showed t(9;11) or t(8;21) with or without del(16)(q22). The 2 patients who had received an epipodophyllotoxin had an 11q23 abnormality. The risk of therapy-related myeloid neoplasia is low in children with malignant solid tumours.

AB - Therapy-related myeloid neoplasia developed 14 to 189 months after diagnosis of the primary malignancy in 12 out of 3365 children treated for malignant solid tumours; 6 of the 12 were in their first complete remission. The 10-year cumulative incidence of myeloid neoplasia was 1·3% (95% Cl 0·5-3·6) for the 447 patients with Hodgkin's disease, 1·3% (0·4-4·3) for the 420 with non-Hodgkin lymphoma, and 1·2% (0·3-5·2) for the 440 with neuroblastoma. This complication appeared in 1 of 180 children with brain tumours and in none of the 1878 with other malignancies. Risk of therapy-related myeloid neoplasia in patients with Hodgkin's disease was associated with recurrence of the primary malignancy, a combination of radiotherapy and chemotherapy with alkylating agents, and age ≥12 years at diagnosis of Hodgkin's disease. Of the 8 patients who underwent chromosomal analysis of neoplastic myeloid cells, 2 showed complete loss of chromosome 7 and 4 showed t(9;11) or t(8;21) with or without del(16)(q22). The 2 patients who had received an epipodophyllotoxin had an 11q23 abnormality. The risk of therapy-related myeloid neoplasia is low in children with malignant solid tumours.

UR - http://www.scopus.com/inward/record.url?scp=0025151128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025151128&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(90)91956-B

DO - 10.1016/0140-6736(90)91956-B

M3 - Article

C2 - 1974952

AN - SCOPUS:0025151128

VL - 336

SP - 417

EP - 421

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8712

ER -